CD274 and neoplasm: Additionally, the microbiome can influence the expression of immune checkpoints within the tumor microenvironment [108], which could directly influence the potential therapeutic efficacy in a given patient of immune checkpoint inhibitors (ICIs) such as anti-PD-1/PD-L1 or anti-CTLA-4 antibodies.